Presence of matrix metalloproteinase-2 and tissue inhibitor matrix metalloproteinase-2 gene polymorphisms and immunohistochemical expressions in intracranial meningiomas

被引:9
|
作者
Coven, Ilker [1 ]
Ozer, Ozge [2 ]
Ozen, Ozlem [3 ]
Sahin, Feride Iffet [2 ]
Altinors, Nur [1 ]
机构
[1] Baskent Univ, Sch Med, Dept Neurosurg, TR-06490 Ankara, Turkey
[2] Baskent Univ, Sch Med, Dept Med Genet, TR-06490 Ankara, Turkey
[3] Baskent Univ, Sch Med, Dept Pathol, TR-06490 Ankara, Turkey
关键词
meningioma; MMP-2; polymorphism; TIMP-2; immunohistochemistry; oncology; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; INVASION; TUMOR; KI-67;
D O I
10.3171/2014.8.JNS13515
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Meningiomas are benign extraaxial tumors with a slow progression. Some of them, in spite of being benign in nature, may show an aggressive progression pattern. To investigate the behavioral characteristics of meningiomas, researchers have studied matrix metalloproteinases (MMPs), their tissue inhibitors (TIMPs), interstitial collagens, proteins, vascular endothelial growth factors (VEGF), and tumor necrosis factors. Methods. In this study, the authors investigated MMP2 and TIMP2 gene polymorphisms in formalin-fixed paraffin-embedded tissue samples obtained from meningioma patients who had previously undergone surgery at the authors' institution. In addition, brain invasion, Ki-67 index, and MMP-2 and TIMP-2 expressions were investigated using immunohistochemical methods. MMP2 (735C>T, 1575G>A, 1306C>T) and TIMP2 (418G>C, 303C>T) gene polymorphisms were investigated from paraffin-embedded tissue sections using the polymerase chain reaction restriction fragment length polymorphism method. Results. There were statistically significant differences between genotype (p = 0.001) and allele frequencies (p = 0.001 and OR 7.4 [95% CI 1.5-36.2]) in patient and control groups for MMP2 1306C>T polymorphism. The authors did not find a statistically significant difference for other polymorphisms. GA genotype was found to be more frequent when brain invasion was suspected for MMP2 1575G>A polymorphism (p = 0.006), There was not a statistically significant difference for other MMP2 or TIMP2 gene polymorphisms. Conclusions. The authors' results support the importance of MMPs and their tissue inhibitors in meningioma pathogenesis. In future studies, these gene polymorphisms, especially MMP2 1306C>T and 1575G>A, should be investigated for meningioma or brain invasion susceptibility in larger study groups.
引用
收藏
页码:1478 / 1482
页数:5
相关论文
共 50 条
  • [1] Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 gene polymorphisms in multiple sclerosis
    Benesova, Y.
    Beranek, M.
    Hladikova, M.
    Vacha, J.
    Kadanka, Z.
    Vasku, A.
    JOURNAL OF NEUROLOGY, 2007, 254 : 68 - 68
  • [2] Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis
    Kang, Shan
    Zhao, Xiwa
    Xing, Huimin
    Wang, Na
    Zhou, Rongmiao
    Chen, Shucheng
    Li, Wansheng
    Zhao, Jian
    Duan, Yanan
    Sun, Donglan
    Li, Yan
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2008, 49 (03) : 226 - 231
  • [3] Matrix metalloproteinase-2 regulates the expression of tissue inhibitor of matrix metalloproteinase-2
    Kimura, Kaoru
    Cheng, Xian Wu
    Nakamura, Kae
    Inoue, Aiko
    Hu, Lina
    Song, Haizhen
    Okumura, Kenji
    Iguchi, Akihisa
    Murohara, Toyoaki
    Kuzuya, Masafumi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (11) : 1096 - 1101
  • [4] Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas
    Okada, M
    Miyake, K
    Matsumoto, Y
    Kawai, N
    Kunishio, K
    Nagao, S
    JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) : 29 - 37
  • [5] Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expressions Correlate with the Recurrence of Intracranial Meningiomas
    Masaki Okada
    Keisuke Miyake
    Yoshihito Matsumoto
    Nobuyuki Kawai
    Katsuzo Kunishio
    Seigo Nagao
    Journal of Neuro-Oncology, 2004, 66 : 29 - 37
  • [6] Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma
    Diao, Lan-Ping
    Ma, Hui
    Wei, Guang-Chuan
    Li, Tao
    Liu, Hai-Sheng
    Liu, Li-Hong
    Wu, Li-Li
    Zhao, Gui-Min
    Gao, Yu-Huan
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : 1095 - 1103
  • [7] Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines
    Afzal, S
    Lalani, EN
    Foulkes, WD
    Boyce, B
    Tickle, S
    Cardillo, MR
    Baker, T
    Pignatelli, M
    Stamp, GWH
    LABORATORY INVESTIGATION, 1996, 74 (02) : 406 - 421
  • [8] Effects of valsartan on matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in atrial fibrillation patients
    裴晓阳
    潘莹
    颜雯
    胡雪松
    SouthChinaJournalofCardiology, 2010, 11 (01) : 15 - 19
  • [9] Expression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in oral squamous cell carcinomas
    Radhakrishnan, R.
    Shrestha, B.
    Bajracharya, D.
    ORAL ONCOLOGY, 2011, 47 : S84 - S84
  • [10] Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma
    Xu, KX
    Hou, SK
    Du, ZJ
    CHINESE MEDICAL JOURNAL, 2002, 115 (05) : 743 - 745